MARKET

CRBP

CRBP

Corbus Pharmaceu
NASDAQ
9.48
+0.46
+5.10%
After Hours: 9.47 -0.01 -0.11% 17:01 02/13 EST
OPEN
9.19
PREV CLOSE
9.02
HIGH
9.51
LOW
8.85
VOLUME
198.38K
TURNOVER
--
52 WEEK HIGH
61.90
52 WEEK LOW
8.50
MARKET CAP
115.46M
P/E (TTM)
-2.0193
1D
5D
1M
3M
1Y
5Y
1D
Corbus Pharmaceuticals Holdings Inc. Stock Rallies 5.1%, Outperforms Competitors
Dow Jones · 3h ago
Analysts Have Conflicting Sentiments on These Healthcare Companies: Corbus Pharmaceuticals (CRBP), Genmab (GMAB) and CVRx (CVRX)
TipRanks · 11h ago
Corbus Pharmaceuticals Holdings Inc. Stock Falls 10.2%, Underperforms Competitors
Dow Jones · 2d ago
Corbus Pharmaceuticals To Present CRB-701 Clinical Data At 2025 ASCO-GU
NASDAQ · 2d ago
Corbus Pharmaceuticals announces clinical data for CRB-701
TipRanks · 2d ago
Corbus Pharmaceuticals Announces Clinical Data for CRB-701 from Western Dose Escalation Study to be Presented at 2025 ASCO-GU
Barchart · 2d ago
Corbus Pharmaceuticals Holdings Inc. Stock Slides 3.6%, Underperforms Market
Dow Jones · 3d ago
Corbus Pharmaceuticals Price Target Cut to $75.00/Share From $80.00 by HC Wainwright & Co.
Dow Jones · 3d ago
More
About CRBP
Corbus Pharmaceuticals Holdings, Inc. is a precision oncology company with a diversified portfolio. The Company's pipeline is comprised of two experimental drugs targeting solid tumors: CRB-701, which is an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload and CRB-601, which is an anti-integrin monoclonal antibody that blocks the activation of TGFβ expressed on cancer cells. Its pipeline also includes CRB-913, which is a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has in-licensed the intellectual property for CRB-601 from Dr. Stephen Nishimura's laboratory at the University of California, San Francisco. The Company does not own or operate manufacturing facilities and relies on third-party contract manufacturing organizations or licensing partners to supply it with drugs for pre-clinical and clinical studies and commercial activities.

Webull offers Corbus Pharmaceuticals Holdings Inc stock information, including NASDAQ: CRBP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CRBP stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CRBP stock methods without spending real money on the virtual paper trading platform.